BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38423784)

  • 1. Development and Preclinical Evaluation of [
    El Fakiri M; Ayada N; Müller M; Hvass L; Gamzov TH; Clausen AS; Geis NM; Steinacker N; Hansson E; Lindegren S; Aneheim E; Jensen H; Eder AC; Jensen AI; Poulie CBM; Kjaer A; Eder M; Herth MM
    J Nucl Med; 2024 Apr; 65(4):593-599. PubMed ID: 38423784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Linker Modification on Tumor-to-Kidney Contrast of
    Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and Evaluation of
    Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
    Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Improved
    Mease RC; Kang CM; Kumar V; Banerjee SR; Minn I; Brummet M; Gabrielson KL; Feng Y; Park A; Kiess AP; Sgouros G; Vaidyanathan G; Zalutsky MR; Pomper MG
    J Nucl Med; 2022 Feb; 63(2):259-267. PubMed ID: 34088772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improve the Biodistribution with Bulky and Lipophilic Modification Strategies on Lys-Urea-Glu-Based PSMA-Targeting Radiotracers.
    Cai P; Tang S; Xia L; Wang Y; Liu Y; Feng Y; Liu N; Chen Y; Zhou Z
    Mol Pharm; 2023 Feb; 20(2):1435-1446. PubMed ID: 36696174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of a novel urea-based
    Zha Z; Ploessl K; Choi SR; Wu Z; Zhu L; Kung HF
    Nucl Med Biol; 2018 Apr; 59():36-47. PubMed ID: 29459281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Halogen Replacement on the Lysine Side Chain of Lys-Urea-Glu-Based PSMA Inhibitors Leads to Significant Changes in Targeting Properties.
    Xia L; Liu Y; Cai P; Feng Y; Yuan H; Tang S; Wang YW; Liu N; Chen Y; Zhou Z
    Mol Imaging Biol; 2023 Aug; 25(4):765-775. PubMed ID: 36695967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo comparative study of a novel
    Chen H; Cai P; Feng Y; Sun Z; Wang Y; Chen Y; Zhang W; Liu N; Zhou Z
    Sci Rep; 2021 Sep; 11(1):19122. PubMed ID: 34580375
    [No Abstract]   [Full Text] [Related]  

  • 12.
    Duan X; Cao Z; Zhu H; Liu C; Zhang X; Zhang J; Ren Y; Liu F; Cai X; Guo X; Xi Z; Pomper MG; Yang Z; Fan Y; Yang X
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1030-1040. PubMed ID: 34453203
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Wu W; Yu F; Zhang P; Bu T; Fu J; Ai S; You Q; Shi L; Shao G; Wang F; Hodolic M; Guo H
    J Nucl Med; 2022 Sep; 63(9):1394-1400. PubMed ID: 35177423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting.
    Moon SH; Hong MK; Kim YJ; Lee YS; Lee DS; Chung JK; Jeong JM
    Bioorg Med Chem; 2018 May; 26(9):2501-2507. PubMed ID: 29655611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Young JD; Abbate V; Imberti C; Meszaros LK; Ma MT; Terry SYA; Hider RC; Mullen GE; Blower PJ
    J Nucl Med; 2017 Aug; 58(8):1270-1277. PubMed ID: 28408532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monosodium Glutamate Reduces
    Rousseau E; Lau J; Kuo HT; Zhang Z; Merkens H; Hundal-Jabal N; Colpo N; Lin KS; Bénard F
    J Nucl Med; 2018 Dec; 59(12):1865-1868. PubMed ID: 30097503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.